3D Systems continues push into bioprinting with Allevi deal
The research community is critical to developing breakthrough innovations in regenerative medicine. 3D Systems, with the addition of Allevi Inc, is now able to provide a robust set of Allevi by 3D Systems bioprinting solutions to researchers and industry giants in hundreds of labs globally.
Allevi is a leading innovator in the bioprinting space with an exclusive focus on the research and development community. Leading laboratories leverage Allevi’s portfolio of hardware, biomaterials and software to design, engineer and build solutions for tissue engineering, organ-on-a-chip research, pharmaceutical validation, biomaterial development, and regenerative medicine.
Allevi desktop 3D bioprinters are among the most versatile, powerful and easy-to-use bioprinters on the market. Customers also have access to a wide range of biomaterials—bioinks, bioink additives, cells, reagents and consumables—as well as an intuitive software interface.
In the medical field, 3D Sytems has delivered additive manufacturing solutions to the healthcare community for more than 30 years. Having produced more than 2,000,000 serial component medical devices and 140,000 patient-specific surgical cases, the company is now scaling the production of bioprinted clinical applications. This technology will elevate patient care through various clinical applications ranging from acellular bioresorbable devices to functionalized solid organs for transplantation.
Before bioprinter hardware manufacturer Allevi, 3D Systems had already entered the bioprinting services market. Together with United Therapeutics Corporation and its organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, the company achieved significant progress in the development of next-generation bioprinting solutions for lung scaffolds that are capable of full size, vascularized, rapid, micron-level printing.
3D Systems’ capabilities as a technology innovator, spanning hardware, software, and materials science, combined with United Therapeutics’ renowned expertise in regenerative medicine has enabled advances in lung modeling, 3D printing, as well as material formulation and material handling to yield significant capabilities in bioprinters and biomaterials for the eventual production of transplantable organs.
To meet the evolving needs of the clinical and R&D communities, 3D Systems continues to push technologies to facilitate advanced application development. The Print to Perfusion process enables 3D printing of high-resolution scaffolds, which can be perfused with living cells to create tissues.
The ability to print large, vascularized, highly detailed hydrogel scaffolds at rapid speeds is opening new opportunities for a range of tissue applications. In addition, we are developing bioprinting solutions that are both commercially viable and scalable from prototype to production.